

[全部](#)[图片](#)[新闻](#)[视频](#)[更多](#)[设置](#)[工具](#)

找到约 58,200 条结果 (用时 0.56 秒)

Google 学术: Anticoagulation with Direct Thrombin Inhibitors during Extracorporeal Membrane Oxygenation

[Argatroban in extracorporeal membrane oxygenation](#) - [Beiderlinden](#) - 被引用次数: 77... [postcardiotomy extracorporeal membrane oxygenation](#) - [Ranucci](#) - 被引用次数: 82... [to heparin in extracorporeal membrane oxygenation](#) ... - [Young](#) - 被引用次数: 37

Anticoagulation Therapy during Extracorporeal Membrane Oxygenator ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457945/> ▾ [翻译此页](#)作者: HJ Cho - 2017 - 被引用次数: 7 - [相关文章](#)[Extracorporeal membrane oxygenation \(ECMO\)](#) is a salvage therapy for Alternative [anticoagulants](#) include [direct thrombin inhibitors](#) (e.g., bivalirudin), factor ...[Abstract](#) · [INTRODUCTION](#) · [HEMORRHAGIC AND ...](#) · [MANAGEMENT OF ...](#)

Anticoagulation in extracorporeal membrane oxygenation - Wong ...

jccm.amegroups.com/article/view/4078/4686 ▾ [翻译此页](#)作者: JJM Wong - 2018 - 被引用次数: 2 - [相关文章](#)2018年2月1日 - Abstract: [During extracorporeal membrane oxygenation \(ECMO\)](#) bivalirudin and lepirudin [[direct thrombin inhibitors](#) (DTI)] are used only by a ...[Introduction](#) · [The pathophysiology of ...](#) · [Anticoagulant agents](#) · [Monitoring of ...](#)

[PDF] ECMO and anticoagulation: a comprehensive review

https://nvc.nl/sites/nvc.nl/files/pdf/review_22.pdf ▾ [翻译此页](#)作者: MMG Mulder - 被引用次数: 7 - [相关文章](#)2018年1月1日 - [during ECMO](#) use remain high at 58% for VV-ECMO and 66% for VA-ECMO. [anticoagulation](#) strategies is required (e.g. [direct thrombin inhibitors](#) ... formation of a heparin-AT complex, which is a [direct inhibitor](#) of factor IIa ...

Traditional and non-traditional anticoagulation management during ...

www.annalscts.com/article/view/16529/16883 ▾ [翻译此页](#)作者: A Koster - 2018 - [相关文章](#)[In](#) selected patients, the HIT antibodies activate platelets and [thrombin](#) generation, promoting thromboembolism (8). Last, but not least, [ECMO](#) will require adequate [anticoagulation](#) in order to avoid fibrin deposition and potentially lethal clot formation.[Introduction](#) · [Monitoring of ...](#) · [Viscoelastic tests and ...](#) · [Alternatives to UFH ...](#)

³
Name of Journal: *World Journal of Critical Care Medicine*

Manuscript NO: 48644

Manuscript Type: REVIEW

Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation

Burstein B *et al.* Anticoagulation during extracorporeal membrane oxygenation

Barry Burstein, Patrick M Wieruszewski, Yan-Jun Zhao, Nathan Smischney

Abstract

Use of extracorporeal membrane oxygenation to support patients with critical cardiorespiratory illness is increasing. Systemic anticoagulation is an essential

Match Overview

1	Crossref 42 words Troy G. Seelhammer, John K. Bohman, Devon O. Aganga, ... mon Maltais, Yanjun Zhao. "Bivalirudin and ECLS", ASAIO J	1%
2	Internet 25 words crawled on 21-Jul-2018 bhingkeyz.com	1%
3	Internet 13 words crawled on 07-Jul-2019 f6publishing.blob.core.windows.net	<1%
4	Crossref 12 words Domenico Paparella, Stephanie J. Brister, Michael R. Buch... an. "Coagulation disorders of cardiopulmonary bypass: a re	<1%
5	Internet 10 words crawled on 20-Mar-2017 en.wikipedia.org	<1%



国内版

国际版

Anticoagulation with direct thrombin inhibitors during extracorporeal membrane c



All

Images

Videos

翻译成中文

关闭取词

170,000 Results

Any time ▾

[PDF] Anticoagulation During Extracorporeal Membrane ...

[https://www.annalsthoracicsurgery.org/article/S0003-4975\(16\)00056-4/pdf](https://www.annalsthoracicsurgery.org/article/S0003-4975(16)00056-4/pdf)

Background. **Heparin** is the main anticoagulant used **during extracorporeal membrane oxygenation** (ECMO) support. Nafamostat mesilate, a synthetic serine protease **inhibitor**, has seen increased use as a substitute for **hep-arin** in patients undergoing ECMO because of its short half-life. We aimed to compare these 2 anticoagulants

Anticoagulation in extracorporeal membrane oxygenation ...

jeccm.amegroups.com/article/view/4078/4686 ▾

Abstract: **During extracorporeal membrane oxygenation** (ECMO) support, the underlying disease process and contact between blood and non-biological surfaces cause alterations in haemostasis. This results in the activation of coagulation and platelet pathways and consumption of factors which can provoke haemorrhage, thrombosis or both.

Cited by: 1

Author: Judith Ju-Ming Wong, Joyce Ching Mei L...

Publish Year: 2018

Anticoagulation and monitoring in pediatric extracorporeal ...

<https://www.sciencedirect.com/science/article/pii/S2090730318300501>

Anticoagulation during extracorporeal membrane oxygenation (ECMO) is necessary to prevent catastrophic circuit clotting, but it can contribute to significant morbidity and mortality for patients. Titrating **anticoagulation** to minimize complications and prevent circuit thrombosis continues to be challenging in spite of the addition of ...

Author: Jamie Weller, Lakshmi Raman, Ali Mc... Publish Year: 2018

(PDF) Anticoagulation in extracorporeal membrane ...

https://www.researchgate.net/publication/322907377_Anticoagulation_in_extracorporeal...

Anticoagulation in **extracorporeal membrane oxygenation**. ... [direct thrombin inhibitors (DTI)] are ... Bleeding is the most common complication **during extracorporeal membrane oxygenation** (ECMO). ...

Anticoagulation During Extracorporeal Membrane ...

<https://www.sciencedirect.com/science/article/pii/S0003497516000564>

Background. **Heparin** is the main anticoagulant used **during extracorporeal membrane oxygenation** (ECMO) support. Nafamostat mesilate, a synthetic serine protease inhibitor, has seen increased use as



国内版

国际版

Anticoagulation with direct thrombin inhibitors during extracorporeal membrane ox



Sign in



All

Images

Videos

翻译成中文

关闭取词

170,000 Results

Any time ▾

[PDF] Anticoagulation During Extracorporeal Membrane ...

[https://www.annalsthoracicsurgery.org/article/S0003-4975\(16\)00056-4/pdf](https://www.annalsthoracicsurgery.org/article/S0003-4975(16)00056-4/pdf)

Background. **Heparin** is the main anticoagulant used **during extracorporeal membrane oxygenation** (ECMO) support. Nafamostat mesilate, a synthetic serine protease **inhibitor**, has seen increased use as a substitute for **hep-arin** in patients undergoing ECMO because of its short half-life. We aimed to compare these 2 anticoagulants

Anticoagulation in extracorporeal membrane oxygenation ...

jccm.amegroups.com/article/view/4078/4686 ▾

Abstract: **During extracorporeal membrane oxygenation** (ECMO) support, the underlying disease process and contact between blood and non-biological surfaces cause alterations in haemostasis. This results in the activation of coagulation and platelet pathways and consumption of factors which can provoke haemorrhage, thrombosis or both.

Cited by: 1

Author: Judith Ju-Ming Wong, Joyce Ching Mei L...

Publish Year: 2018

Anticoagulation and monitoring in pediatric extracorporeal ...

<https://www.sciencedirect.com/science/article/pii/S2090730318300501>

Anticoagulation during extracorporeal membrane oxygenation (ECMO) is necessary to prevent catastrophic circuit clotting, but it can contribute to significant morbidity and mortality for patients. Titrating **anticoagulation** to minimize complications and prevent circuit thrombosis continues to be challenging in spite of the addition of ...

Author: Jamie Weller, Lakshmi Raman, Ali Mc...

Publish Year: 2018